| Literature DB >> 31853185 |
Bing Han1,2, Jiawei Huang3, Zhenjie Yang1, Jiaqi Zhang3, Xiaomin Wang3, Ning Xu3, Haining Meng3, Junyu Wu3, Qiao Huang3, Xi Yang3, Ruowu Shen3, Chuandong Sun1.
Abstract
PURPOSE: To explore the effect of miR-449a inhibits migration and invasion by targeting Notch1 and regulating epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma (HCC), and further study on the molecular mechanism. PATIENTS AND METHODS: The expression of miR-449a and Notch1 in HCC cells and tissues was detected by qRT-PCR. The HCC cell line HCCLM3 and SMMC-7721 were transfected with miR-449a. The invasion and migration of HCC cell lines were detected by transwell assay and wound healing assay. The Notch pathway and EMT related protein were detected with Western Blotting. The specific binding site of mir-449a on notch1 gene was detected by luciferase assay.Entities:
Keywords: bioinformatics; epithelial-mesenchymal transition; microRNA; signal pathway
Year: 2019 PMID: 31853185 PMCID: PMC6916688 DOI: 10.2147/OTT.S216997
Source DB: PubMed Journal: Onco Targets Ther ISSN: 1178-6930 Impact factor: 4.147
Figure 1Small RNA sequencing and miR-449a expression in HCC tissue. (A) Left-Volcano plot for small RNA sequencing screening. The fold change was miRNA expression in short-term recurrence group (n=8) vs non-recurrence group (n=8). The miR-449a was one of the significantly downregulated miRNAs in HCC tissues with recurrence in 6 months. Right-The expression of miR-449a in non-relapse (n=34) and relapse (n=16) groups. (B) The expression of miR-449a was positively related to disease-free survival and overall survival of HCC patients. The mean miR-449a expression was used as cutoff value. The Kaplan–Meier analysis was used to estimate survival for the two groups. (C) The relative expression of mir-449a was significantly higher in HCC tissues than in adjacent nontumor tissues. Conversely, the Notch1 expression reduced in HCC tissues significantly. (D) The relative expression of mir-449a and Notch1 in HCC cell lines and hepatocyte cell line. *p<0.05, **p<0.01, ***p<0.001.
Clinicopathological Characteristics of Patient in Short-Term Recurrence and Non-recurrence Groups
| Variables | Short Term Recurrence | ||||
|---|---|---|---|---|---|
| No (n=34) | Yes (n=16) | ||||
| Age (y) | 58.38±11.26 | 54.38±10.70 | 1.19 | 0.239 | |
| Gender (M/F) | 27/7 | 13/3 | 0.023 | 0.880 | |
| Tumor number | 1.03±0.17 | 1.06±0.25 | −0.547 | 0.587 | |
| Tumor size (cm) | 4.24±2.57 | 5.63±3.30 | −1.632 | 0.109 | |
| Tumor margin (cm) | 8.12±8.38 | 6.51±4.84 | 0.855 | 0.397 | |
| Pathologic differentiation(low/high) | 29/5 | 11/5 | 1.861 | 0.172 | |
| Capsule invasion | 8/34 | 7/16 | 2.118 | 0.146 | |
| Vascular invasion | 6/34 | 3/16 | 0.009 | 0.925 | |
| Liver cirrhosis | 31/34 | 13/16 | 1.015 | 0.314 | |
| HBV infection | 30/34 | 13/16 | 0.441 | 0.507 | |
| miR-449a | 3.59±0.63 | 5.43 ± 0.47 | 2.260 | ||
Notes: Bold value represents statistically significant p<0.05. The data in this table were cited from a paper that our team have published.17
Univariate and Multivariate Analyses of Various Prognostic Parameters in Patients with HCC Cox-Regression Analysis for DFS
| Univariate Analysis | Multivariate Analysis | |||||
|---|---|---|---|---|---|---|
| P-value | HR | 95% CI | p-value | HR | 95% CI | |
| miR-449a | 0.204 | 0.090–0.461 | 0.001* | 0.231 | 0.101–529 | |
| Notch1 | 0.403 | 0.932 | 0.791–1.099 | |||
| Age (y) | 0.229 | 0.979 | 0.946–1.013 | |||
| Gender | 0.361 | 1.641 | 0.567–4.749 | |||
| AFP | 0.265 | 1.578 | 0.708–3.521 | |||
| Tumor number | 0.402 | 1.853 | 0.438–7.838 | |||
| Tumor size (cm) | 0.199 | 1.690 | 0.758–3.767 | |||
| Tumor margin (cm) | 0.332 | 0.346 | 0.151–0.795 | |||
| Pathologic differentiation | 2.532 | 1.186–5.406 | ||||
| Vascular invasion | 0.708 | 1.189 | 0.479–2.950 | |||
| Capsule invasion | 0.074 | 2.021 | 0.933–4.379 | |||
| Liver cirrhosis | 0.396 | 0.631 | 0.218–1.827 | |||
| HBV infection | 0.365 | 0.638 | 0.241–1.687 | |||
Note: *p < 0.05, statistically significant.
Abbreviations: HCC, hepatocellular carcinoma; DFS, disease-free survival; HR, hazard ratio; CI, confidence interval.
Univariate and Multivariate Analyses of Various Prognostic Parameters in Patients with HCC Cox-regression Analysis for OS
| Univariate Analysis | Multivariate Analysis | |||||
|---|---|---|---|---|---|---|
| P-value | HR | 95% CI | p-value | HR | 95% CI | |
| miR-449a | 0.008* | 0.241 | 0.085–0.687 | 0.014* | 0.265 | 0.092–0.762 |
| Notch1 | 0.943 | 0.966 | 0.372–2.504 | |||
| Age(y) | 0.317 | 0.611 | 0.232–1.606 | |||
| Gender | 0.339 | 2.054 | 0.469–8.987 | |||
| AFP | 0.298 | 1.697 | 0.626–4.596 | |||
| Tumor number | 0.082 | 3.725 | 0.848–16.371 | |||
| Tumor size (cm) | 0.537 | 1.389 | 0.489–3.946 | |||
| Tumor margin (cm) | 0.137 | 0.452 | 0.159–1.287 | |||
| Pathologic differentiation | 0.033* | 2.833 | 1.086–7.386 | |||
| Vascular invasion | 0.969 | 0.976 | 0.280–3.400 | |||
| Capsule invasion | 0.276 | 1.712 | 0.650–4.507 | |||
| Liver cirrhosis | 0.071 | 0.353 | 0.114–1.091 | |||
| HBV infection | 0.224 | 0.498 | 1.162–1.530 | |||
Note: *p < 0.05, statistically significant.
Figure 2miR-449a inhibited the migration and invasion levels of HCC cells. (A) The results of migration assays for SMMC-7721 and HCCLM4 after transfected. (B) The results of invasion assays for SMMC-7721 and HCCLM3 after transfected. *p<0.05, **p<0.01 and ***p<0.001 compared with control group.
Figure 3miR-449a mimics and miR-449a inhibitor had influenced the gene expression both in SMMC-7721 and HCCLM3 cell lines. (A) The putative sequences of miR-449a and Notch1 with one binding site. (B) miR-449a significantly inhibited the luciferase activity of the wild-type reporter for Notch1; however, miR-449a did not inhibit the luciferase activity of the reporter vector containing the mutant binding sites of Notch1 in SMMC-7721. (C) The relative levels of miR-449a were up-regulated after transfected with miR-449a mimics while was down-regulated after transfected with miR-449a inhibitor compared with their own NC vector in both cell lines. (D) The relative levels of Notch1 mRNA were up-regulated after being transfected with miR-449a inhibitor and were down-regulated in miR-449a mimics group compared with their own NC vector in both cell lines. (E, F) The expression levels of Notch1 protein were up-regulated after being transfected with miR-449a inhibitor while was down-regulated in miR-449a mimics group compared with their own NC vector in SMMC-7721(E) and HCCLM3(F). *p<0.05, **p<0.01, and ***p<0.001 compared with the control group.
Figure 4miR-449a affected migration and invasion of HCC cell lines by regulating EMT. (A) Western Blot assays for E-cadherin and Vimentin expression in SMMC-7721 after transfection. (B) Western Blot assays for E-cadherin and Vimentin expression in HCCLM3 after transfection. *p<0.05, **p<0.01, and ***p<0.001 compared with control group.
Figure 5miR-449a affected Notch Signaling Pathway. (A) Western Blot assays for Cleaved Notch1 and c-Myc expression in SMMC-7721 after transfection. (B) Western Blot assays for Cleaved Notch1 and c-Myc expression in HCCLM3 after transfection. **p<0.01, and ***p<0.001 compared with control group.
Figure 6The mechanism of miR-449a in regulating Notch Signaling Pathway.